Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
NCT06654050 · National Cancer Institute (NCI) · PHASE2 · withdrawn · last registry update 2026-03-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study is being withdrawn due to the CRADA with the company not being finalized” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TP53 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-10Results posted on the registry: National Cancer Institute (NCI), Carfilzomib + Dexamethasone (NCT03031730)
- 2026-02-10Also stopped (terminated): National Cancer Institute (NCI), Carfilzomib + Dexamethasone (NCT03031730)
- 2025-11-13Also stopped (terminated): National Cancer Institute (NCI), Navtemadlin (NCT03107780)
- 2025-10-10Also stopped (terminated): Novartis Pharmaceuticals, HDM201 + MBG453 (NCT03940352)
- 2025-08-07Results posted on the registry: Novartis Pharmaceuticals, Ruxolitinib + Siremadlin (NCT04097821)
- 2025-08-07Also stopped (terminated): Novartis Pharmaceuticals, Ruxolitinib + Siremadlin (NCT04097821)
- 2025-05-16Also stopped (terminated): Novartis Pharmaceuticals, Siremadlin (NCT05447663)
- 2025-05-13Results posted on the registry: Aprea Therapeutics, APR-246 (eprenetapopt) + Pembrolizumab (NCT04383938)
- 2025-03-17Also stopped (terminated): Aprea Therapeutics, APR-246 (eprenetapopt) + Acalabrutinib in CLL + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL (NCT04419389)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision